2020
DOI: 10.1111/dth.13862
View full text
|
Sign up to set email alerts
|
Share

Abstract: used to treat SJS/TEN, recent evidence suggests that TNF-α inhibitors are promising candidates for monotherapy, second-line therapy, and combination therapy for SJS/TEN. Our patient's epidermolysis did not improve in the first 4 days of receiving systemic glucocorticoids and immunoglobulin. We therefore administered etanercept, our aim being to combat the major role of TNF-α in epithelial cell death. The combination of glucocorticoids, immunoglobulin, and etanercept achieved a good clinical response. Our exper…

Expand abstract